7 reasons why it is worth to use glimepiride in the treatment of type 2 diabetes Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
glimepiride, sulfonylureas, type 2 diabetes
Main Article Content
Abstract
Type 2 diabetes mellitus is becoming more and more common diagnosis. Failure in compliance with therapeutic lifestyle change leads to introduction of pharmacotherapy. Recently several novel antidiabetic drugs have been introduced to the clinic. Nevertheless, there are still ongoing trials that should put these novel drugs into the perspective of current treatment of diabetes. Till then it is imperative not to forget about older, commonly used and effective antidiabetic drugs that are currently available on the market. Sulfonylureas, especially those belonging to II and III generation (e.g. glimepiride) are one of those drugs.
Article Details
How to Cite
Okopień, B., & Bułdak, Łukasz. (2017). 7 reasons why it is worth to use glimepiride in the treatment of type 2 diabetes. Medycyna Faktow (J EBM), 10(1(34), 42-46. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2193
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. WHO. Diabetes [online] dostęp: luty 2017 r.
2. World Health Organization. Diabetes country profiles, 2016 [online] dostęp: luty 2017 r.
3. Olszanecka-Glinianowicz M.: Leczenie farmakologiczne otyłości w świetle aktualnych wytycznych American Association of Clinical Endocrinologists i American College of Endocrinology 2016. Medycyna Praktyczna, Kraków 2017; 1: 52-61.
4. Goldberg R.B., Holvey S.M., Schneider J.: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996; 19(8): 849-856.
5. Amate J.M., Lopez-Cuadrado T., Almendro N. et al.: Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int. J. Clin. Pract. 2015; 69(3): 292-304.
6. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2016; 5(supl. A).
7. Charakterystyka Produktu Leczniczego [online].
8. Matsuki M., Matsuda M., Kohara K. et al.: Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocr. J. 2007; 54(4): 571-576.
9. Basit A., Riaz M., Fawwad A.: Glimepiride: evidence-based facts, trends, and observations (GIFTS). [Corrected]. Vasc. Health Risk. Manag. 2012; 8: 463-472.
10. Charakterystyka Produktu Leczniczego Amaryl [online].
11. Davis S.N.: Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert. Rev. Clin. Pharmacol. 2014; 7(1): 21-23.
12. Andersen S.E., Christensen M.: Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br. J. Clin. Pharmacol. 2016; 82(5): 1291-1302.
13. Joy N.G., Tate D.B., Davis S.N.: Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non-diabetic individuals. Metabolism. 2015; 64(6): 729-737.
14. Saulsberry W.J., Coleman C.I., Mearns E.S. et al.: Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int. J. Clin. Pract. 2015; 69(11): 1221-1235.
15. Tomai F., Crea F., Gaspardone A. et al.: Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994; 90(2): 700-705.
16. Mocanu M.M., Maddock H.L., Baxter G.F. et al.: Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001; 103(25): 3111-3116.
17. Simpson S.H., Lee J., Choi S. et al.: Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015; 3(1): 43-51.
18. Umpierrez G., Issa M., Vlajnic A.: Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr. Med. Res. Opin. 2006; 22(4): 751-759.
19. Gudipaty L., Rosenfeld N.K., Fuller C.S. et al.: Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes. Diabetes Care. 2014; 37(9): 2451-2458.
2. World Health Organization. Diabetes country profiles, 2016 [online] dostęp: luty 2017 r.
3. Olszanecka-Glinianowicz M.: Leczenie farmakologiczne otyłości w świetle aktualnych wytycznych American Association of Clinical Endocrinologists i American College of Endocrinology 2016. Medycyna Praktyczna, Kraków 2017; 1: 52-61.
4. Goldberg R.B., Holvey S.M., Schneider J.: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996; 19(8): 849-856.
5. Amate J.M., Lopez-Cuadrado T., Almendro N. et al.: Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int. J. Clin. Pract. 2015; 69(3): 292-304.
6. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2016; 5(supl. A).
7. Charakterystyka Produktu Leczniczego [online].
8. Matsuki M., Matsuda M., Kohara K. et al.: Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocr. J. 2007; 54(4): 571-576.
9. Basit A., Riaz M., Fawwad A.: Glimepiride: evidence-based facts, trends, and observations (GIFTS). [Corrected]. Vasc. Health Risk. Manag. 2012; 8: 463-472.
10. Charakterystyka Produktu Leczniczego Amaryl [online].
11. Davis S.N.: Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert. Rev. Clin. Pharmacol. 2014; 7(1): 21-23.
12. Andersen S.E., Christensen M.: Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br. J. Clin. Pharmacol. 2016; 82(5): 1291-1302.
13. Joy N.G., Tate D.B., Davis S.N.: Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non-diabetic individuals. Metabolism. 2015; 64(6): 729-737.
14. Saulsberry W.J., Coleman C.I., Mearns E.S. et al.: Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int. J. Clin. Pract. 2015; 69(11): 1221-1235.
15. Tomai F., Crea F., Gaspardone A. et al.: Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994; 90(2): 700-705.
16. Mocanu M.M., Maddock H.L., Baxter G.F. et al.: Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001; 103(25): 3111-3116.
17. Simpson S.H., Lee J., Choi S. et al.: Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015; 3(1): 43-51.
18. Umpierrez G., Issa M., Vlajnic A.: Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr. Med. Res. Opin. 2006; 22(4): 751-759.
19. Gudipaty L., Rosenfeld N.K., Fuller C.S. et al.: Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes. Diabetes Care. 2014; 37(9): 2451-2458.